Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) Sublingual Immunotherapy (SLIT)-Tablet in Children and Adolescents (5-17 Years) With HDM Allergic Asthma

NCT03654976 is registered in ClinicalTrials.gov with ALK-Abelló A/S as lead sponsor.

NCT NCT03654976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03654976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) Sublingual Immunotherapy (SLIT)-Tablet in Children and Adolescents (5-17 Years) With HDM Allergic Asthma
Lead sponsor
ALK-Abelló A/S
Phase
Phase 3
Overall status
Completed
Start date
February 22, 2018
Completion date
May 31, 2022
Enrollment
533 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

allergic asthma due to dermatophagoides farinae, allergic asthma due to dermatophagoides pteronyssinus, allergic rhinitis due to house dust mite